SINGAPORE, Dec. 8, 2010 /PRNewswire-Asia/ -- From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network).
Participants will be discussing strategies to tackle global public health challenges including appropriate pandemic surveillance programs, low cost and fast vaccine manufacturing technologies, innovative adjuvants and delivery systems, vaccine research funding opportunities and the latest clinical results of new and next generation vaccines fighting life-threatening infectious diseases such as cholera, malaria, dengue, AIDS and rotavirus infection, just to name a few.
As a matter of fact, over 9.5 million people die each year due to infectious diseases – nearly all live in developing countries.
Current vaccines and past vaccination programs have now controlled 10 major infectious diseases. Unfortunately, many of these diseases, except for smallpox, are still rampant in third world and developing countries, which can mean a comeback anywhere, where vaccines begin to be delayed or stopped.
The Indian vaccine industry has always played an important role in helping the world fight infectious diseases. According to Biotechnology Industry Organization, the Indian vaccine industry currently caters to 60 to 70 percent of global requirement of basic vaccines procured by U.N. agencies for children. In addition to this, Indian vaccine manufacturers are also partners in several global initiatives to develop cost-effective vaccines against the threats of H1N1, meningitis, Japanese encephalitis, etc.
However, challenges such as "access to new technology", "increasing cost", "inadequate disease burden data", "funding", "multiple set of regulation and regulators" still remain as major stumbling blocks for Indian vaccine manufactur
|SOURCE IMAPAC Pte Ltd|
Copyright©2010 PR Newswire.
All rights reserved